Drugs / DA-3803
DA-3803
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01718119 | Feb 2012 → Feb 2013 | female infertility | Dong-A Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-3803 | “The subjects are randomized into 2 groups. One group receive DA-3803(r-hCG) 250mcg and the other group receive Ovidrel®(r-hCG)250mcg.” NCT01718119 ↗ |
| Known as | Ovidrel | “The subjects are randomized into 2 groups. One group receive DA-3803(r-hCG) 250mcg and the other group receive Ovidrel®(r-hCG)250mcg.” NCT01718119 ↗ |
| Known as | r-hCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01718119 ↗ |
| Modality | Protein / enzyme biologic | “DA-3803(Recombinant Human Chorionic Gonadotrophin)” NCT01718119 ↗ |
| Route | Subcutaneous | “injection subcutaneously” NCT01718119 ↗ |